Summary

The global Contract Pharmaceutical Manufacturing market is projected to grow from US$ 146631 million in 2025 to US$ 242110 million by 2032, at a CAGR of 7.2% (2026-2032), driven by critical product segments and diverse end‑use applications.
Contract Pharmaceutical Manufacturing refers to third-party pharmaceutical development and manufacturing activities performed under contractual arrangements for pharmaceutical and biotechnology companies. The research object covers services extending from process, formulation and analytical development through technology transfer, scale-up and GMP manufacturing to commercial supply and packaging, creating a manufacturing bridge between drug development and market supply. The principal service forms are API CDMO, FDF CDMO, Packaging CDMO and Clinical CDMO. Depending on the project stage, providers may undertake chemical synthesis, formulation, fill-finish, biological processing, analytical testing, clinical-batch manufacturing, packaging, labeling, quality control and related technical support. Contract Pharmaceutical Manufacturing is therefore characterized by regulated production, technology transfer, process reproducibility, manufacturing scale-up and lifecycle continuity, with pharmaceutical companies and biotechnology companies representing the principal downstream customer groups.
Key Findings
Asia Pacific accounted for 36.54% of 2025 market value
API CDMO remained the largest service segment in 2025
FDF CDMO is projected to become the largest type by 2032
Pharmaceutical companies represented 62.74% of 2025 market demand
Top five providers represented about 14.15% of 2025 revenue Market Trends
Contract Pharmaceutical Manufacturing is moving from capacity-based outsourcing toward deeper integration across development, technology transfer, manufacturing and commercial supply. Customers increasingly evaluate providers not only on available production assets but also on their ability to manage complex processes, shorten transfers between development and commercial stages, maintain consistent quality systems and support multiple product lifecycle phases within one network. This favors providers capable of combining drug substance and drug product capabilities, while demand for sterile manufacturing, advanced formulations, biologics-related production and other technically demanding programs raises the importance of specialized infrastructure. At the same time, manufacturing networks are becoming more geographically diversified as customers place greater emphasis on supply continuity and regional responsiveness. Digital manufacturing systems, automation, process monitoring and standardized technology-transfer platforms are also becoming more important for improving reproducibility and asset utilization. Recent expansion and operating strategies among major providers reinforce the direction toward integrated platforms, larger manufacturing readiness and closer coordination between development and commercial production.
Market Dynamics
Drivers
The principal driver for Contract Pharmaceutical Manufacturing is the continuing economic and operational logic of pharmaceutical outsourcing. Building and maintaining GMP facilities requires substantial capital investment, specialized personnel and continuous quality-system expenditure, while internal demand for individual assets may fluctuate substantially as pipelines progress or fail. Contract manufacturing allows pharmaceutical and biotechnology companies to convert part of this fixed manufacturing burden into project-based expenditure and gain access to capabilities that would be costly or slow to establish internally. The expansion of complex drug pipelines further increases the need for specialist process development, scale-up, sterile production, formulation and analytical capabilities. Smaller biotechnology companies are particularly dependent on external infrastructure, while larger pharmaceutical companies increasingly use external partners to supplement internal networks, manage peak capacity, localize supply and accelerate commercialization. Regulatory frameworks also formalize the responsibilities of owners and contract facilities, reinforcing the importance of qualified manufacturing partners with established quality systems and auditable operating processes.
Restraints
Contract Pharmaceutical Manufacturing remains constrained by high fixed investment, lengthy qualification cycles and the operational rigidity associated with regulated pharmaceutical production. New capacity must often be installed well before revenue visibility is fully established, creating utilization risk when customer programs are delayed, reformulated or terminated. Technology transfer and process validation can require extensive documentation, analytical comparability and engineering work, making supplier switching significantly more difficult than in conventional industrial outsourcing. Regulatory compliance also increases operating costs because quality responsibilities, change control, documentation, audits and batch-related oversight must remain clearly defined between the sponsor and manufacturing facility. For strategically important products, some large pharmaceutical companies continue to retain selected manufacturing capabilities internally to protect supply security, intellectual property or critical process know-how. These factors limit the extent to which outsourcing can replace internal pharmaceutical manufacturing and favor providers with sufficient scale, technical depth and balance-sheet capacity to absorb long investment cycles.
Opportunities
The largest structural opportunity in Contract Pharmaceutical Manufacturing lies in moving from isolated manufacturing tasks toward higher-value, multi-stage customer relationships. Projects that begin in clinical development can create follow-on opportunities in process optimization, validation, commercial manufacturing, packaging and lifecycle supply, allowing providers to deepen customer relationships without repeatedly acquiring new programs. FDF CDMO is particularly well positioned as pharmaceutical products move from development into commercial dosage-form production and as sterile and technically complex finished products require specialized infrastructure. Integrated drug substance and drug product programs also create opportunities for providers able to reduce handoffs between suppliers and simplify technology transfer. Beyond individual service steps, additional value can be created through flexible batch sizes, regional manufacturing footprints, analytical support and supply-chain coordination. The increasing use of integrated manufacturing agreements and continued capacity investment among leading providers indicate that customers are placing greater value on partners capable of supporting both clinical and commercial stages within a coordinated network.
Challenges
The central challenge for Contract Pharmaceutical Manufacturing is balancing rapid capacity expansion with quality consistency and sustainable utilization. Pharmaceutical manufacturing assets are highly specialized, and mismatches between installed capacity and customer pipelines can materially affect returns. At the same time, customer programs are becoming more technically demanding, requiring providers to recruit and retain experienced personnel across process engineering, analytical development, quality assurance and regulatory operations. Global manufacturing networks also face increasing complexity in procurement, technology transfer, logistics and cross-border quality coordination. Any major deviation, inspection issue, contamination event or delivery delay can affect not only one batch but also long-term customer confidence and future contract awards. Competition further raises the threshold for differentiation: basic production capacity alone is increasingly insufficient, while investment in specialized technologies must be supported by adequate project flow. Providers therefore need to combine technical depth, reliable execution, regulatory discipline and disciplined capacity planning rather than pursuing expansion based solely on headline capacity.
Industry Chain Analysis
The Contract Pharmaceutical Manufacturing industry chain begins with suppliers of pharmaceutical starting materials, chemical intermediates, solvents, reagents, excipients, biological-process inputs, single-use components, primary packaging materials, laboratory consumables and production equipment. The midstream consists of contract manufacturers that convert these inputs and customer technology packages into development batches, clinical materials, APIs, finished dosage forms and packaged pharmaceutical products. Value creation occurs through process development, technology transfer, scale-up, validation, GMP manufacturing, analytical control, quality management and reliable delivery rather than through production capacity alone. The downstream consists mainly of pharmaceutical and biotechnology companies that retain product ownership and commercialization responsibility while outsourcing selected development or manufacturing activities. Profitability across the chain is strongly influenced by manufacturing complexity, capacity utilization, batch size, yield, labor intensity, quality requirements and the extent to which material costs can be passed through to customers. Commodity-like manufacturing tends to face greater pricing pressure, whereas technically difficult processes, scarce capacity and integrated development-to-commercial capabilities can support stronger customer retention and higher value capture. Long qualification periods and regulatory switching costs also create customer stickiness once a program has been successfully transferred, but they simultaneously increase the cost of operational failures. As a result, the economic quality of a Contract Pharmaceutical Manufacturing platform depends increasingly on project mix, asset utilization and execution reliability rather than nominal installed capacity alone.
Segment Insights
API CDMO remained the largest Contract Pharmaceutical Manufacturing segment in 2025, accounting for approximately 40.48% of market value, while FDF CDMO represented approximately 34.39%. The structure is expected to shift over the forecast period: by 2032, FDF CDMO is projected to rise to approximately 38.33%, overtaking API CDMO at approximately 35.94%. This transition indicates that incremental market value is increasingly moving toward dosage-form manufacturing and downstream commercialization services rather than remaining concentrated primarily in drug-substance production. API CDMO nevertheless remains a foundational part of the market because process chemistry, synthesis, scale-up and drug-substance supply determine the manufacturability and continuity of many pharmaceutical programs. Packaging CDMO maintains a meaningful role as serialization, labeling, primary packaging and market-specific presentation become more tightly integrated with commercial supply, while Clinical CDMO addresses smaller-batch and development-stage requirements where flexibility and turnaround time are critical. The most attractive competitive positions are therefore likely to emerge where providers can connect multiple service categories while retaining specialized technical capability within each stage. This does not imply that integrated providers will displace specialized manufacturers; niche suppliers can remain competitive where process expertise, asset specialization or customer responsiveness outweighs the benefits of a broader platform.
Downstream Market Opportunities
Pharmaceutical companies represented approximately 62.74% of Contract Pharmaceutical Manufacturing demand in 2025 and remain the largest customer group, reflecting their extensive outsourcing requirements across clinical supply, APIs, finished dosage forms and packaging. Biotechnology companies accounted for approximately 34.77%, but their share is projected to increase to about 35.92% by 2032, indicating a gradual shift toward customers that typically operate with more asset-light manufacturing models. The commercial opportunity differs by customer type: large pharmaceutical groups value global networks, supply assurance, regulatory track records and multi-product capability, while biotechnology companies place greater weight on development support, flexible batch scales, speed of transfer and access to specialized manufacturing infrastructure. Providers that can serve a project from clinical development through commercial production can capture a larger share of customer lifecycle spending and reduce the risk of losing programs during scale-up or launch.
Regional Insights
Asia Pacific was the largest regional Contract Pharmaceutical Manufacturing market in 2025 with a 36.54% share and is projected to increase to approximately 38.12% by 2032. The region combines a large pharmaceutical production base with expanding capabilities in APIs, finished dosage forms and biologics-related manufacturing, supporting a growing role in global outsourcing networks. North America remains the second major market and retains strong demand for technically complex, regulated and commercial-stage manufacturing, while Europe continues to benefit from a mature pharmaceutical industry, established GMP infrastructure and specialized manufacturing capabilities. The resulting regional structure is therefore not based purely on labor-cost differences; technical capability, regulatory track record, proximity to customers, supply-chain resilience and availability of specialized capacity increasingly determine where projects are awarded. Current capacity strategies among leading providers also point toward more geographically balanced manufacturing networks designed to support regional supply and reduce concentration risk.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Contract Pharmaceutical Manufacturing market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Lonza
Catalent
Thermo Fisher Scientific
Samsung Biologics
Fareva
WuXi AppTech
WuXi Biologics
Siegfried
FUJIFILM Diosynth Biotechnologies
Asymchem
Pfizer CentreOne
Delpharm
Recipharm
AGC Pharma Chemicals
Boehringer Ingelheim
Vetter
Curia
Aenova
Porton
Piramal
Strides Pharma
NextPharma
Famar
Jubilant
Alcami
Euroapi
Eurofins
Avid Bioservices
BioVectra
CPL
Segment by Type
API CMO
FDF CMO
Packaging CMO
Clinical CMO
Segment by Drug Molecules
Small Molecule CMO
Biologics CMO
Cell & Gene Therapy CMO
Peptide & Oligonucleotide CMO
Segment by Dosage Form
Oral Solid Dose CMO
Sterile Injectable CMO
Liquid & Semi-solid Dosage Form CMO
Inhalation & Nasal Drug CMO
Other Dosage Form CMO
Segment by Application
Pharmaceutical Company
Biotechnology Company
Other
Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Contract Pharmaceutical Manufacturing study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Contract Pharmaceutical Manufacturing: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Contract Pharmaceutical Manufacturing Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 API CMO
1.2.3 FDF CMO
1.2.4 Packaging CMO
1.2.5 Clinical CMO
1.3 Market Segmentation by Drug Molecules
1.3.1 Global Contract Pharmaceutical Manufacturing Market Size by Drug Molecules, 2021 vs 2025 vs 2032
1.3.2 Small Molecule CMO
1.3.3 Biologics CMO
1.3.4 Cell & Gene Therapy CMO
1.3.5 Peptide & Oligonucleotide CMO
1.4 Market Segmentation by Dosage Form
1.4.1 Global Contract Pharmaceutical Manufacturing Market Size by Dosage Form, 2021 vs 2025 vs 2032
1.4.2 Oral Solid Dose CMO
1.4.3 Sterile Injectable CMO
1.4.4 Liquid & Semi-solid Dosage Form CMO
1.4.5 Inhalation & Nasal Drug CMO
1.4.6 Other Dosage Form CMO
1.5 Market Segmentation by Application
1.5.1 Global Contract Pharmaceutical Manufacturing Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Pharmaceutical Company
1.5.3 Biotechnology Company
1.5.4 Other
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Contract Pharmaceutical Manufacturing Revenue Estimates and Forecasts (2021-2032)
2.2 Global Contract Pharmaceutical Manufacturing Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape
3.1 Global Contract Pharmaceutical Manufacturing Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Contract Pharmaceutical Manufacturing Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 API CMO: Market Share by Key Players
3.3.2 FDF CMO: Market Share by Key Players
3.3.3 Packaging CMO: Market Share by Key Players
3.3.4 Clinical CMO: Market Share by Key Players
3.4 Global Contract Pharmaceutical Manufacturing Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation
4.1 Global Contract Pharmaceutical Manufacturing Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global Contract Pharmaceutical Manufacturing Market by Drug Molecules
4.2.1 Global Revenue by Drug Molecules (2021-2032)
4.2.2 Global Revenue-Based Market Share by Drug Molecules (2021-2032)
4.3 Global Contract Pharmaceutical Manufacturing Market by Dosage Form
4.3.1 Global Revenue by Dosage Form (2021-2032)
4.3.2 Global Revenue-Based Market Share by Dosage Form (2021-2032)
4.4 Key Product Attributes and Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Contract Pharmaceutical Manufacturing Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application

6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Contract Pharmaceutical Manufacturing Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Contract Pharmaceutical Manufacturing Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico

7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Contract Pharmaceutical Manufacturing Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Contract Pharmaceutical Manufacturing Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia

8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Contract Pharmaceutical Manufacturing Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Contract Pharmaceutical Manufacturing Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore

9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Contract Pharmaceutical Manufacturing Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Contract Pharmaceutical Manufacturing Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Contract Pharmaceutical Manufacturing Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Contract Pharmaceutical Manufacturing Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 Lonza
11.1.1 Lonza Corporation Information
11.1.2 Lonza Business Overview
11.1.3 Lonza Contract Pharmaceutical Manufacturing Product Features and Attributes
11.1.4 Lonza Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
11.1.5 Lonza Contract Pharmaceutical Manufacturing Revenue by Product in 2025
11.1.6 Lonza Contract Pharmaceutical Manufacturing Revenue by Application in 2025
11.1.7 Lonza Contract Pharmaceutical Manufacturing Revenue by Geographic Area in 2025
11.1.8 Lonza Contract Pharmaceutical Manufacturing SWOT Analysis
11.1.9 Lonza Recent Developments
11.2 Catalent
11.2.1 Catalent Corporation Information
11.2.2 Catalent Business Overview
11.2.3 Catalent Contract Pharmaceutical Manufacturing Product Features and Attributes
11.2.4 Catalent Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
11.2.5 Catalent Contract Pharmaceutical Manufacturing Revenue by Product in 2025
11.2.6 Catalent Contract Pharmaceutical Manufacturing Revenue by Application in 2025
11.2.7 Catalent Contract Pharmaceutical Manufacturing Revenue by Geographic Area in 2025
11.2.8 Catalent Contract Pharmaceutical Manufacturing SWOT Analysis
11.2.9 Catalent Recent Developments
11.3 Thermo Fisher Scientific
11.3.1 Thermo Fisher Scientific Corporation Information
11.3.2 Thermo Fisher Scientific Business Overview
11.3.3 Thermo Fisher Scientific Contract Pharmaceutical Manufacturing Product Features and Attributes
11.3.4 Thermo Fisher Scientific Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
11.3.5 Thermo Fisher Scientific Contract Pharmaceutical Manufacturing Revenue by Product in 2025
11.3.6 Thermo Fisher Scientific Contract Pharmaceutical Manufacturing Revenue by Application in 2025
11.3.7 Thermo Fisher Scientific Contract Pharmaceutical Manufacturing Revenue by Geographic Area in 2025
11.3.8 Thermo Fisher Scientific Contract Pharmaceutical Manufacturing SWOT Analysis
11.3.9 Thermo Fisher Scientific Recent Developments
11.4 Samsung Biologics
11.4.1 Samsung Biologics Corporation Information
11.4.2 Samsung Biologics Business Overview
11.4.3 Samsung Biologics Contract Pharmaceutical Manufacturing Product Features and Attributes
11.4.4 Samsung Biologics Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
11.4.5 Samsung Biologics Contract Pharmaceutical Manufacturing Revenue by Product in 2025
11.4.6 Samsung Biologics Contract Pharmaceutical Manufacturing Revenue by Application in 2025
11.4.7 Samsung Biologics Contract Pharmaceutical Manufacturing Revenue by Geographic Area in 2025
11.4.8 Samsung Biologics Contract Pharmaceutical Manufacturing SWOT Analysis
11.4.9 Samsung Biologics Recent Developments
11.5 Fareva
11.5.1 Fareva Corporation Information
11.5.2 Fareva Business Overview
11.5.3 Fareva Contract Pharmaceutical Manufacturing Product Features and Attributes
11.5.4 Fareva Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
11.5.5 Fareva Contract Pharmaceutical Manufacturing Revenue by Product in 2025
11.5.6 Fareva Contract Pharmaceutical Manufacturing Revenue by Application in 2025
11.5.7 Fareva Contract Pharmaceutical Manufacturing Revenue by Geographic Area in 2025
11.5.8 Fareva Contract Pharmaceutical Manufacturing SWOT Analysis
11.5.9 Fareva Recent Developments
11.6 WuXi AppTech
11.6.1 WuXi AppTech Corporation Information
11.6.2 WuXi AppTech Business Overview
11.6.3 WuXi AppTech Contract Pharmaceutical Manufacturing Product Features and Attributes
11.6.4 WuXi AppTech Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
11.6.5 WuXi AppTech Recent Developments
11.7 WuXi Biologics
11.7.1 WuXi Biologics Corporation Information
11.7.2 WuXi Biologics Business Overview
11.7.3 WuXi Biologics Contract Pharmaceutical Manufacturing Product Features and Attributes
11.7.4 WuXi Biologics Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
11.7.5 WuXi Biologics Recent Developments
11.8 Siegfried
11.8.1 Siegfried Corporation Information
11.8.2 Siegfried Business Overview
11.8.3 Siegfried Contract Pharmaceutical Manufacturing Product Features and Attributes
11.8.4 Siegfried Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
11.8.5 Siegfried Recent Developments
11.9 FUJIFILM Diosynth Biotechnologies
11.9.1 FUJIFILM Diosynth Biotechnologies Corporation Information
11.9.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.9.3 FUJIFILM Diosynth Biotechnologies Contract Pharmaceutical Manufacturing Product Features and Attributes
11.9.4 FUJIFILM Diosynth Biotechnologies Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
11.9.5 FUJIFILM Diosynth Biotechnologies Recent Developments
11.10 Asymchem
11.10.1 Asymchem Corporation Information
11.10.2 Asymchem Business Overview
11.10.3 Asymchem Contract Pharmaceutical Manufacturing Product Features and Attributes
11.10.4 Asymchem Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 Pfizer CentreOne
11.11.1 Pfizer CentreOne Corporation Information
11.11.2 Pfizer CentreOne Business Overview
11.11.3 Pfizer CentreOne Contract Pharmaceutical Manufacturing Product Features and Attributes
11.11.4 Pfizer CentreOne Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
11.11.5 Pfizer CentreOne Recent Developments
11.12 Delpharm
11.12.1 Delpharm Corporation Information
11.12.2 Delpharm Business Overview
11.12.3 Delpharm Contract Pharmaceutical Manufacturing Product Features and Attributes
11.12.4 Delpharm Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
11.12.5 Delpharm Recent Developments
11.13 Recipharm
11.13.1 Recipharm Corporation Information
11.13.2 Recipharm Business Overview
11.13.3 Recipharm Contract Pharmaceutical Manufacturing Product Features and Attributes
11.13.4 Recipharm Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
11.13.5 Recipharm Recent Developments
11.14 AGC Pharma Chemicals
11.14.1 AGC Pharma Chemicals Corporation Information
11.14.2 AGC Pharma Chemicals Business Overview
11.14.3 AGC Pharma Chemicals Contract Pharmaceutical Manufacturing Product Features and Attributes
11.14.4 AGC Pharma Chemicals Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
11.14.5 AGC Pharma Chemicals Recent Developments
11.15 Boehringer Ingelheim
11.15.1 Boehringer Ingelheim Corporation Information
11.15.2 Boehringer Ingelheim Business Overview
11.15.3 Boehringer Ingelheim Contract Pharmaceutical Manufacturing Product Features and Attributes
11.15.4 Boehringer Ingelheim Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
11.15.5 Boehringer Ingelheim Recent Developments
11.16 Vetter
11.16.1 Vetter Corporation Information
11.16.2 Vetter Business Overview
11.16.3 Vetter Contract Pharmaceutical Manufacturing Product Features and Attributes
11.16.4 Vetter Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
11.16.5 Vetter Recent Developments
11.17 Curia
11.17.1 Curia Corporation Information
11.17.2 Curia Business Overview
11.17.3 Curia Contract Pharmaceutical Manufacturing Product Features and Attributes
11.17.4 Curia Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
11.17.5 Curia Recent Developments
11.18 Aenova
11.18.1 Aenova Corporation Information
11.18.2 Aenova Business Overview
11.18.3 Aenova Contract Pharmaceutical Manufacturing Product Features and Attributes
11.18.4 Aenova Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
11.18.5 Aenova Recent Developments
11.19 Porton
11.19.1 Porton Corporation Information
11.19.2 Porton Business Overview
11.19.3 Porton Contract Pharmaceutical Manufacturing Product Features and Attributes
11.19.4 Porton Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
11.19.5 Porton Recent Developments
11.20 Piramal
11.20.1 Piramal Corporation Information
11.20.2 Piramal Business Overview
11.20.3 Piramal Contract Pharmaceutical Manufacturing Product Features and Attributes
11.20.4 Piramal Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
11.20.5 Piramal Recent Developments
11.21 Strides Pharma
11.21.1 Strides Pharma Corporation Information
11.21.2 Strides Pharma Business Overview
11.21.3 Strides Pharma Contract Pharmaceutical Manufacturing Product Features and Attributes
11.21.4 Strides Pharma Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
11.21.5 Strides Pharma Recent Developments
11.22 NextPharma
11.22.1 NextPharma Corporation Information
11.22.2 NextPharma Business Overview
11.22.3 NextPharma Contract Pharmaceutical Manufacturing Product Features and Attributes
11.22.4 NextPharma Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
11.22.5 NextPharma Recent Developments
11.23 Famar
11.23.1 Famar Corporation Information
11.23.2 Famar Business Overview
11.23.3 Famar Contract Pharmaceutical Manufacturing Product Features and Attributes
11.23.4 Famar Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
11.23.5 Famar Recent Developments
11.24 Jubilant
11.24.1 Jubilant Corporation Information
11.24.2 Jubilant Business Overview
11.24.3 Jubilant Contract Pharmaceutical Manufacturing Product Features and Attributes
11.24.4 Jubilant Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
11.24.5 Jubilant Recent Developments
11.25 Alcami
11.25.1 Alcami Corporation Information
11.25.2 Alcami Business Overview
11.25.3 Alcami Contract Pharmaceutical Manufacturing Product Features and Attributes
11.25.4 Alcami Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
11.25.5 Alcami Recent Developments
11.26 Euroapi
11.26.1 Euroapi Corporation Information
11.26.2 Euroapi Business Overview
11.26.3 Euroapi Contract Pharmaceutical Manufacturing Product Features and Attributes
11.26.4 Euroapi Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
11.26.5 Euroapi Recent Developments
11.27 Eurofins
11.27.1 Eurofins Corporation Information
11.27.2 Eurofins Business Overview
11.27.3 Eurofins Contract Pharmaceutical Manufacturing Product Features and Attributes
11.27.4 Eurofins Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
11.27.5 Eurofins Recent Developments
11.28 Avid Bioservices
11.28.1 Avid Bioservices Corporation Information
11.28.2 Avid Bioservices Business Overview
11.28.3 Avid Bioservices Contract Pharmaceutical Manufacturing Product Features and Attributes
11.28.4 Avid Bioservices Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
11.28.5 Avid Bioservices Recent Developments
11.29 BioVectra
11.29.1 BioVectra Corporation Information
11.29.2 BioVectra Business Overview
11.29.3 BioVectra Contract Pharmaceutical Manufacturing Product Features and Attributes
11.29.4 BioVectra Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
11.29.5 BioVectra Recent Developments
11.30 CPL
11.30.1 CPL Corporation Information
11.30.2 CPL Business Overview
11.30.3 CPL Contract Pharmaceutical Manufacturing Product Features and Attributes
11.30.4 CPL Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
11.30.5 CPL Recent Developments

12 Contract Pharmaceutical Manufacturing Value Chain and Ecosystem Analysis
12.1 Contract Pharmaceutical Manufacturing Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Contract Pharmaceutical Manufacturing Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Contract Pharmaceutical Manufacturing Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Contract Pharmaceutical Manufacturing Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Contract Pharmaceutical Manufacturing Market Size Growth Rate by Drug Molecules, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Contract Pharmaceutical Manufacturing Market Size Growth Rate by Dosage Form, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Contract Pharmaceutical Manufacturing Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Contract Pharmaceutical Manufacturing Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Contract Pharmaceutical Manufacturing Revenue by Region (US$ Million), 2021-2026
Table 7. Global Contract Pharmaceutical Manufacturing Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Contract Pharmaceutical Manufacturing Revenue by Players (US$ Million), 2021-2026
Table 10. Global Contract Pharmaceutical Manufacturing Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Contract Pharmaceutical Manufacturing Revenue, 2025
Table 13. Global Contract Pharmaceutical Manufacturing Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Contract Pharmaceutical Manufacturing Companies Headquarters
Table 15. Global Contract Pharmaceutical Manufacturing Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Contract Pharmaceutical Manufacturing Revenue by Type (US$ Million), 2021-2026
Table 19. Global Contract Pharmaceutical Manufacturing Revenue by Type (US$ Million), 2027-2032
Table 20. Global Contract Pharmaceutical Manufacturing Revenue by Drug Molecules (US$ Million), 2021-2026
Table 21. Global Contract Pharmaceutical Manufacturing Revenue by Drug Molecules (US$ Million), 2027-2032
Table 22. Global Contract Pharmaceutical Manufacturing Revenue by Dosage Form (US$ Million), 2021-2026
Table 23. Global Contract Pharmaceutical Manufacturing Revenue by Dosage Form (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Contract Pharmaceutical Manufacturing Revenue by Application (US$ Million), 2021-2026
Table 26. Global Contract Pharmaceutical Manufacturing Revenue by Application (US$ Million), 2027-2032
Table 27. Contract Pharmaceutical Manufacturing High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Contract Pharmaceutical Manufacturing Growth Accelerators and Market Barriers
Table 31. North America Contract Pharmaceutical Manufacturing Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Contract Pharmaceutical Manufacturing Growth Accelerators and Market Barriers
Table 33. Europe Contract Pharmaceutical Manufacturing Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Contract Pharmaceutical Manufacturing Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Contract Pharmaceutical Manufacturing Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Contract Pharmaceutical Manufacturing Investment Opportunities and Key Challenges
Table 37. Central and South America Contract Pharmaceutical Manufacturing Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Contract Pharmaceutical Manufacturing Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Contract Pharmaceutical Manufacturing Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. Lonza Corporation Information
Table 41. Lonza Description and Major Businesses
Table 42. Lonza Product Features and Attributes
Table 43. Lonza Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. Lonza Revenue Proportion by Product in 2025
Table 45. Lonza Revenue Proportion by Application in 2025
Table 46. Lonza Revenue Proportion by Geographic Area in 2025
Table 47. Lonza Contract Pharmaceutical Manufacturing SWOT Analysis
Table 48. Lonza Recent Developments
Table 49. Catalent Corporation Information
Table 50. Catalent Description and Major Businesses
Table 51. Catalent Product Features and Attributes
Table 52. Catalent Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Catalent Revenue Proportion by Product in 2025
Table 54. Catalent Revenue Proportion by Application in 2025
Table 55. Catalent Revenue Proportion by Geographic Area in 2025
Table 56. Catalent Contract Pharmaceutical Manufacturing SWOT Analysis
Table 57. Catalent Recent Developments
Table 58. Thermo Fisher Scientific Corporation Information
Table 59. Thermo Fisher Scientific Description and Major Businesses
Table 60. Thermo Fisher Scientific Product Features and Attributes
Table 61. Thermo Fisher Scientific Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. Thermo Fisher Scientific Revenue Proportion by Product in 2025
Table 63. Thermo Fisher Scientific Revenue Proportion by Application in 2025
Table 64. Thermo Fisher Scientific Revenue Proportion by Geographic Area in 2025
Table 65. Thermo Fisher Scientific Contract Pharmaceutical Manufacturing SWOT Analysis
Table 66. Thermo Fisher Scientific Recent Developments
Table 67. Samsung Biologics Corporation Information
Table 68. Samsung Biologics Description and Major Businesses
Table 69. Samsung Biologics Product Features and Attributes
Table 70. Samsung Biologics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. Samsung Biologics Revenue Proportion by Product in 2025
Table 72. Samsung Biologics Revenue Proportion by Application in 2025
Table 73. Samsung Biologics Revenue Proportion by Geographic Area in 2025
Table 74. Samsung Biologics Contract Pharmaceutical Manufacturing SWOT Analysis
Table 75. Samsung Biologics Recent Developments
Table 76. Fareva Corporation Information
Table 77. Fareva Description and Major Businesses
Table 78. Fareva Product Features and Attributes
Table 79. Fareva Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. Fareva Revenue Proportion by Product in 2025
Table 81. Fareva Revenue Proportion by Application in 2025
Table 82. Fareva Revenue Proportion by Geographic Area in 2025
Table 83. Fareva Contract Pharmaceutical Manufacturing SWOT Analysis
Table 84. Fareva Recent Developments
Table 85. WuXi AppTech Corporation Information
Table 86. WuXi AppTech Description and Major Businesses
Table 87. WuXi AppTech Product Features and Attributes
Table 88. WuXi AppTech Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. WuXi AppTech Recent Developments
Table 90. WuXi Biologics Corporation Information
Table 91. WuXi Biologics Description and Major Businesses
Table 92. WuXi Biologics Product Features and Attributes
Table 93. WuXi Biologics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. WuXi Biologics Recent Developments
Table 95. Siegfried Corporation Information
Table 96. Siegfried Description and Major Businesses
Table 97. Siegfried Product Features and Attributes
Table 98. Siegfried Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. Siegfried Recent Developments
Table 100. FUJIFILM Diosynth Biotechnologies Corporation Information
Table 101. FUJIFILM Diosynth Biotechnologies Description and Major Businesses
Table 102. FUJIFILM Diosynth Biotechnologies Product Features and Attributes
Table 103. FUJIFILM Diosynth Biotechnologies Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. FUJIFILM Diosynth Biotechnologies Recent Developments
Table 105. Asymchem Corporation Information
Table 106. Asymchem Description and Major Businesses
Table 107. Asymchem Product Features and Attributes
Table 108. Asymchem Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. Asymchem Recent Developments
Table 110. Pfizer CentreOne Corporation Information
Table 111. Pfizer CentreOne Description and Major Businesses
Table 112. Pfizer CentreOne Product Features and Attributes
Table 113. Pfizer CentreOne Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Pfizer CentreOne Recent Developments
Table 115. Delpharm Corporation Information
Table 116. Delpharm Description and Major Businesses
Table 117. Delpharm Product Features and Attributes
Table 118. Delpharm Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. Delpharm Recent Developments
Table 120. Recipharm Corporation Information
Table 121. Recipharm Description and Major Businesses
Table 122. Recipharm Product Features and Attributes
Table 123. Recipharm Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. Recipharm Recent Developments
Table 125. AGC Pharma Chemicals Corporation Information
Table 126. AGC Pharma Chemicals Description and Major Businesses
Table 127. AGC Pharma Chemicals Product Features and Attributes
Table 128. AGC Pharma Chemicals Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. AGC Pharma Chemicals Recent Developments
Table 130. Boehringer Ingelheim Corporation Information
Table 131. Boehringer Ingelheim Description and Major Businesses
Table 132. Boehringer Ingelheim Product Features and Attributes
Table 133. Boehringer Ingelheim Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. Boehringer Ingelheim Recent Developments
Table 135. Vetter Corporation Information
Table 136. Vetter Description and Major Businesses
Table 137. Vetter Product Features and Attributes
Table 138. Vetter Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. Vetter Recent Developments
Table 140. Curia Corporation Information
Table 141. Curia Description and Major Businesses
Table 142. Curia Product Features and Attributes
Table 143. Curia Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. Curia Recent Developments
Table 145. Aenova Corporation Information
Table 146. Aenova Description and Major Businesses
Table 147. Aenova Product Features and Attributes
Table 148. Aenova Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. Aenova Recent Developments
Table 150. Porton Corporation Information
Table 151. Porton Description and Major Businesses
Table 152. Porton Product Features and Attributes
Table 153. Porton Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. Porton Recent Developments
Table 155. Piramal Corporation Information
Table 156. Piramal Description and Major Businesses
Table 157. Piramal Product Features and Attributes
Table 158. Piramal Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. Piramal Recent Developments
Table 160. Strides Pharma Corporation Information
Table 161. Strides Pharma Description and Major Businesses
Table 162. Strides Pharma Product Features and Attributes
Table 163. Strides Pharma Revenue (US$ Million) and Gross Margin (2021-2026)
Table 164. Strides Pharma Recent Developments
Table 165. NextPharma Corporation Information
Table 166. NextPharma Description and Major Businesses
Table 167. NextPharma Product Features and Attributes
Table 168. NextPharma Revenue (US$ Million) and Gross Margin (2021-2026)
Table 169. NextPharma Recent Developments
Table 170. Famar Corporation Information
Table 171. Famar Description and Major Businesses
Table 172. Famar Product Features and Attributes
Table 173. Famar Revenue (US$ Million) and Gross Margin (2021-2026)
Table 174. Famar Recent Developments
Table 175. Jubilant Corporation Information
Table 176. Jubilant Description and Major Businesses
Table 177. Jubilant Product Features and Attributes
Table 178. Jubilant Revenue (US$ Million) and Gross Margin (2021-2026)
Table 179. Jubilant Recent Developments
Table 180. Alcami Corporation Information
Table 181. Alcami Description and Major Businesses
Table 182. Alcami Product Features and Attributes
Table 183. Alcami Revenue (US$ Million) and Gross Margin (2021-2026)
Table 184. Alcami Recent Developments
Table 185. Euroapi Corporation Information
Table 186. Euroapi Description and Major Businesses
Table 187. Euroapi Product Features and Attributes
Table 188. Euroapi Revenue (US$ Million) and Gross Margin (2021-2026)
Table 189. Euroapi Recent Developments
Table 190. Eurofins Corporation Information
Table 191. Eurofins Description and Major Businesses
Table 192. Eurofins Product Features and Attributes
Table 193. Eurofins Revenue (US$ Million) and Gross Margin (2021-2026)
Table 194. Eurofins Recent Developments
Table 195. Avid Bioservices Corporation Information
Table 196. Avid Bioservices Description and Major Businesses
Table 197. Avid Bioservices Product Features and Attributes
Table 198. Avid Bioservices Revenue (US$ Million) and Gross Margin (2021-2026)
Table 199. Avid Bioservices Recent Developments
Table 200. BioVectra Corporation Information
Table 201. BioVectra Description and Major Businesses
Table 202. BioVectra Product Features and Attributes
Table 203. BioVectra Revenue (US$ Million) and Gross Margin (2021-2026)
Table 204. BioVectra Recent Developments
Table 205. CPL Corporation Information
Table 206. CPL Description and Major Businesses
Table 207. CPL Product Features and Attributes
Table 208. CPL Revenue (US$ Million) and Gross Margin (2021-2026)
Table 209. CPL Recent Developments
Table 210. Technologies, Platforms and Infrastructure
Table 211. Distributors List
Table 212. Market Trends and Market Evolution
Table 213. Market Drivers and Opportunities
Table 214. Market Challenges, Risks, and Restraints
Table 215. Research Programs/Design for This Report
Table 216. Key Data Information from Secondary Sources
Table 217. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Contract Pharmaceutical Manufacturing Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. API CMO Product Picture
Figure 3. FDF CMO Product Picture
Figure 4. Packaging CMO Product Picture
Figure 5. Clinical CMO Product Picture
Figure 6. Global Contract Pharmaceutical Manufacturing Market Size Growth Rate by Drug Molecules, 2021 vs 2025 vs 2032 (US$ Million)
Figure 7. Small Molecule CMO Product Picture
Figure 8. Biologics CMO Product Picture
Figure 9. Cell & Gene Therapy CMO Product Picture
Figure 10. Peptide & Oligonucleotide CMO Product Picture
Figure 11. Global Contract Pharmaceutical Manufacturing Market Size Growth Rate by Dosage Form, 2021 vs 2025 vs 2032 (US$ Million)
Figure 12. Oral Solid Dose CMO Product Picture
Figure 13. Sterile Injectable CMO Product Picture
Figure 14. Liquid & Semi-solid Dosage Form CMO Product Picture
Figure 15. Inhalation & Nasal Drug CMO Product Picture
Figure 16. Other Dosage Form CMO Product Picture
Figure 17. Global Contract Pharmaceutical Manufacturing Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 18. Pharmaceutical Company
Figure 19. Biotechnology Company
Figure 20. Other
Figure 21. Contract Pharmaceutical Manufacturing Report Years Considered
Figure 22. Global Contract Pharmaceutical Manufacturing Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 23. Global Contract Pharmaceutical Manufacturing Revenue (US$ Million), 2021-2032
Figure 24. Global Contract Pharmaceutical Manufacturing Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 25. Global Contract Pharmaceutical Manufacturing Revenue-Based Market Share by Region (2021-2032)
Figure 26. Global Contract Pharmaceutical Manufacturing Revenue-Based Market Share Ranking (2025)
Figure 27. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 28. API CMO Revenue-Based Market Share by Player in 2025
Figure 29. FDF CMO Revenue-Based Market Share by Player in 2025
Figure 30. Packaging CMO Revenue-Based Market Share by Player in 2025
Figure 31. Clinical CMO Revenue-Based Market Share by Player in 2025
Figure 32. Global Contract Pharmaceutical Manufacturing Revenue-Based Market Share by Type (2021-2032)
Figure 33. Global Contract Pharmaceutical Manufacturing Revenue-Based Market Share by Drug Molecules (2021-2032)
Figure 34. Global Contract Pharmaceutical Manufacturing Revenue-Based Market Share by Dosage Form (2021-2032)
Figure 35. Global Contract Pharmaceutical Manufacturing Revenue-Based Market Share by Application (2021-2032)
Figure 36. North America Contract Pharmaceutical Manufacturing Revenue YoY (US$ Million), 2021-2032
Figure 37. North America Top 5 Players Contract Pharmaceutical Manufacturing Revenue (US$ Million) in 2025
Figure 38. North America Contract Pharmaceutical Manufacturing Revenue (US$ Million) by Application (2021-2032)
Figure 39. US Contract Pharmaceutical Manufacturing Revenue (US$ Million), 2021-2032
Figure 40. Canada Contract Pharmaceutical Manufacturing Revenue (US$ Million), 2021-2032
Figure 41. Mexico Contract Pharmaceutical Manufacturing Revenue (US$ Million), 2021-2032
Figure 42. Europe Contract Pharmaceutical Manufacturing Revenue YoY (US$ Million), 2021-2032
Figure 43. Europe Top 5 Players Contract Pharmaceutical Manufacturing Revenue (US$ Million) in 2025
Figure 44. Europe Contract Pharmaceutical Manufacturing Revenue (US$ Million) by Application (2021-2032)
Figure 45. Germany Contract Pharmaceutical Manufacturing Revenue (US$ Million), 2021-2032
Figure 46. France Contract Pharmaceutical Manufacturing Revenue (US$ Million), 2021-2032
Figure 47. U.K. Contract Pharmaceutical Manufacturing Revenue (US$ Million), 2021-2032
Figure 48. Italy Contract Pharmaceutical Manufacturing Revenue (US$ Million), 2021-2032
Figure 49. Russia Contract Pharmaceutical Manufacturing Revenue (US$ Million), 2021-2032
Figure 50. Asia-Pacific Contract Pharmaceutical Manufacturing Revenue YoY (US$ Million), 2021-2032
Figure 51. Asia-Pacific Top 8 Players Contract Pharmaceutical Manufacturing Revenue (US$ Million) in 2025
Figure 52. Asia-Pacific Contract Pharmaceutical Manufacturing Revenue (US$ Million) by Application (2021-2032)
Figure 53. Indonesia Contract Pharmaceutical Manufacturing Revenue (US$ Million), 2021-2032
Figure 54. Japan Contract Pharmaceutical Manufacturing Revenue (US$ Million), 2021-2032
Figure 55. South Korea Contract Pharmaceutical Manufacturing Revenue (US$ Million), 2021-2032
Figure 56. Australia Contract Pharmaceutical Manufacturing Revenue (US$ Million), 2021-2032
Figure 57. India Contract Pharmaceutical Manufacturing Revenue (US$ Million), 2021-2032
Figure 58. Indonesia Contract Pharmaceutical Manufacturing Revenue (US$ Million), 2021-2032
Figure 59. Vietnam Contract Pharmaceutical Manufacturing Revenue (US$ Million), 2021-2032
Figure 60. Malaysia Contract Pharmaceutical Manufacturing Revenue (US$ Million), 2021-2032
Figure 61. Philippines Contract Pharmaceutical Manufacturing Revenue (US$ Million), 2021-2032
Figure 62. Singapore Contract Pharmaceutical Manufacturing Revenue (US$ Million), 2021-2032
Figure 63. Central and South America Contract Pharmaceutical Manufacturing Revenue YoY (US$ Million), 2021-2032
Figure 64. Central and South America Top 5 Players Contract Pharmaceutical Manufacturing Revenue (US$ Million) in 2025
Figure 65. Central and South America Contract Pharmaceutical Manufacturing Revenue (US$ Million) by Application (2021-2032)
Figure 66. Brazil Contract Pharmaceutical Manufacturing Revenue (US$ Million), 2021-2032
Figure 67. Argentina Contract Pharmaceutical Manufacturing Revenue (US$ Million), 2021-2032
Figure 68. Middle East and Africa Contract Pharmaceutical Manufacturing Revenue YoY (US$ Million), 2021-2032
Figure 69. Middle East and Africa Top 5 Players Contract Pharmaceutical Manufacturing Revenue (US$ Million) in 2025
Figure 70. Middle East and Africa Contract Pharmaceutical Manufacturing Revenue (US$ Million) by Application (2021-2032)
Figure 71. GCC Countries Contract Pharmaceutical Manufacturing Revenue (US$ Million), 2021-2032
Figure 72. Israel Contract Pharmaceutical Manufacturing Revenue (US$ Million), 2021-2032
Figure 73. Egypt Contract Pharmaceutical Manufacturing Revenue (US$ Million), 2021-2032
Figure 74. South Africa Contract Pharmaceutical Manufacturing Revenue (US$ Million), 2021-2032
Figure 75. Contract Pharmaceutical Manufacturing Value Chain Mapping
Figure 76. Channels of Distribution (Direct Vs Distribution)
Figure 77. Bottom-up and Top-down Approaches for This Report
Figure 78. Data Triangulation
Figure 79. Key Executives Interviewed